Medscape: New Data Spotlight Safety of HF Telehealth Visits in the Pandemic

The rapid transition to and reliance on telehealth to manage patients with heart failure (HF) during the COVID-19 pandemic does not appear to impact clinical outcomes, according to real-world data.

HF outpatients managed with telehealth visits did not show a significantly higher adjusted risk for subsequent emergency department (ED) visits, hospital admissions, intensive care use, or death at 30 and 90 days, the investigators report in JACC: Heart Failure.

Dr. Brett Sperry, senior author of the study and cardiologist at Saint Luke's Mid America Heart Institute, talked to Medscape Cardiology about the findings.

"Telehealth is safe and effective in probably some of our highest-risk patients who traditionally have needed hands-on, in-person assessment and evaluation — those patients who have heart failure — so we shouldn't be afraid to use it all the time, not when needed as a minimum," Sperry said.

Read the full Medscape article: New Data Spotlight Safety of HF Telehealth Visits in the Pandemic

Related Content

Apr. 27, 2020

NBC Nightly News: Doctors turn to telemedicine for routine visits as hospitals face coronavirus crisis
Virtual visits are becoming much more common as patients stay home amid the coronavirus pandemic. NBC Nightly News talked to doctors at Saint Luke's Mid America Heart Institute about how they are utilizing the technology to deliver the best patient care.
Sep. 30, 2021

New York Times: How Much Exercise Do We Need to Live Longer?
Two large-scale new studies of the relationship between physical activity and longevity show that the right types and amounts of physical activity reduce the risk of premature death by as much as 70 percent.
Sep. 15, 2021

TCTMD: PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF
Dapagliflozin eases symptoms and physical limitations among patients who have heart failure with preserved ejection fraction (HFpEF) within a relatively short time period.